Research Interests:

My special areas of interest are within the field of Multiple Sclerosis and related disorders and broadly include three overlapping themes: magnetic resonance imaging (MRI) related research, clinical trials in MS, and special populations and emerging forms of MS.

BSc McGill University, Montreal, QC Biology
BSc Dalhousie Medical School, Halifax, NS Medicine
FRCPC University of British Columbia Neurology
MD Dalhousie Medical School, Halifax, NS Medicine
Recent Publications:
  • Huang, R. Abugharbieh R, Tam R, Traboulsee A:  Automatic MRI brain tissue segmentation using a hybrid statistical and geometric model. IEEE International Symposium on Biomedical Imaging (ISBI), 2006;pp. 394-397.
  • Huang, R. Abugharbieh R, Tam R, Traboulsee A:  Brain extraction using geodesic active contours. SPIE Medical Imaging, 2006;pp. 61444J 1-8.
  • Huang, R. Abugharbieh R, Tam R, Traboulsee A: Hybrid framework for automatic 3D brain extraction and segmentation.  IEEE International Symposium on Signal Processing and Information Technology (ISSPIT) 2006;pp. 107-111.
  • Ishaq G, Hamarneh, Tam R, Traboulsee A: Effects of mid-sagittal plan perturbation and image interpolation on corpus callosum area calculation. IEEE Symposium on Signal Processing and Information Technology (ISSPIT), 2006;pp. 197-202.
  • Kappos L. Traboulsee A, Constantinescu C, Eralinna JP, Correstal F, Jongen P et al. Long-Term subcutaneous interferon beta-1a therapy in patients with relapsing remitting MS. Neurology 2006;67(6):944-953.
  • Laule C, Leung E, Li DIB, Traboulsee AL, Paty DW, MacKay AL et al. Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology. Multiple Sclerosis 2006:12;747-753.
  • Li DKB, Li MJ, Traboulsee A, Zhao G, Riddehough A, Paty D: The use of MRI as an outcome measure in clinical trials.  Advances in Neurology, 2006;98:203-226.
  • Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F et al. Standardized MR imaging protocol for multiple sclerosis. American Journal of Neuroradiology 2006;27(2):455-461.
  • Traboulsee AL, Li DK: The role of MRI in the diagnosis of multiple sclerosis. Adv Neurology 2006;98:125-146.
  • Ishaq O, Hamarneh G, Tam R, Traboulsee A: Longitudinal, regional and deformation-specific corpus callosum shape analysis for multiple sclerosis.  Conference Proceedings of the IEEE Engineering in Medicine and Biology Society 1:2110-2113, 2007.
  • Laule C, Vavasour IM, Kolind SH, Li DK, Traboulsee A, Moore GR, MacKay AL: Magnetic resonance imaging of myelin. Neurotherapeutics 2007:4(3):460-484.
  • Laule C, Vavasour IM, Kolind SH, Traboulsee AL, Moore GR, Li DKB, MacKay A: Long T2 water in multiple sclerosis: What else can we learn from multi-echo T2 relaxation? Journal of Neurology 2007:11:1579-1587.
  • Laule C, Vavasour IM, Madler B, Kolind SH, Sirrs SM, Brief EE, Traboulsee AL et al. MR evidence of long T2 water in pathological white matter. Journal Magnetic Resonance Imaging.  Magnetic Resonance Imaging 2007:26(4):1117-1121.
  • Traboulsee A: MRI relapses have significant pathologic and clinical implications in multiple sclerosis.  Journal of Neurological Sciences 2007;256(Suppl 1);S19-22.
  • Vavasour IM, Li DK, Laule C, Traboulsee AL, Moore GR, MacKay AL: Multi-parametric MR assessment of T1 black holes in multiple sclerosis: Evidence that myelin loss is not greater in hypointense versus isointense T1 lesions. Journal of Neurology 2007:12:1653-1659.
  • Kolind SH, Laule C, Vavasour IM, Li DK, Traboulsee AL, Madler B, Moore GR, Mackay AL: Complementary information from multi-exponential T2 relaxation and diffusion tensor imaging reveals differences between multiple sclerosis lesions. Neuroimage 2008; 40(1);77-95.
  • Moore GR, Laule C, Mackay A, Leung E, Li DK, Zhao G, Traboulsee AL, Paty DW: Dirty-appearing white matter in multiple sclerosis: preliminary observations of myeline phospholipid and axonal loss. J Neurol Sci 2008;(11):1802-1822.
  • Rieckmann P, Traboulsee A, Devonshire V, Oger J: Escalating immunotherapy of multiple sclerosis. Therapeutic Advances in Neurological Disorders 1(3) pg. 181-192, 2008.
  • Traboulsee A, Al-Sabbagh A, Bennett R, Change P, Li DK, EVIDENCE Study Group, UBC MS/MRI Research Group. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) study. BMC Neurol 2008 Apr 21;8:11.
  • Traboulsee A, Li DKB: Conventional MR imaging. Neuroimag Clin N Am.  2008:(4):651-673.
  • Zhao Y, Traboulsee A, Petkau AJ, Li D: Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. Neurology 2008:70:1092-1097.
  • De Jager PL, Chibnik LB, Cui J, et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 2009;8:1111-1119.
  • Ebers GC, Reder AT, Traboulsee, A, Li D, Langdon D, Goodin DS, Wolf C, Beckmann K, Konieczny A; Investigators of the 16-Year Long-Term Follow-Up Study. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther. 2009 Aug;31(8):1724-36.
  • Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-997.
  • MacKay AL, Vavasour IM, Rauscher A, et al. MR Relaxation in Multiple Sclerosis. Neuroimaging clinics of North America 2009;19(1):1-26 (CA).
  • Metz LM, Li D, Traboulsee A, et al. Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Multiple Sclerosis 2009;15:1183-1194.
  • Meyers SM, Laule C, Vavasour IM, Kolind SH, Madler B, Tam R, Traboulsee AL et al. Reproducibility of myelin water fraction analysis: a comparison or region of interest and voxel-based analysis methods. Magnetic Resonance Imaging 2009;27:1096-1103.
  • O’Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-897.
  • Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009;73:1616-1623.
  • Tremlett H, Zhao Y, Devonshire V. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. Journal of Neurology 2009;256:374-381.
  • Vavasour IM, Laule C, Li DK, Oger J, Moore GR, Traboulsee, A, MacKay AL Longitudinal changes in myelin water fraction in two MS patients with active disease.. J Neurol Sci. 2009 Jan 15;276(1-2):49-53.
  • Vavasour IM, Laule C, Li DKB, et al. Longitudinal changes in myelin water fraction in two MS patients with active disease. Journal of the Neurological Sciences 2009;276:49-53.
  • Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosur Ps 2010;81:907-912.
  • Kingwell E, Leung AL, Roger E, et al. Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. Journal of the Neurological Sciences 2010;292:57-62.
  • Koch M, Zhao Y, Yee I, et al. Disease onset in familial and sporadic primary progressive multiple sclerosis. Multiple Sclerosis 2010;16:694-700.
  • Laule C, Vavasour IM, Zhao Y, et al. Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis. Multiple Sclerosis 2010;16:670-677.
  • Reder AT, Ebers GC, Traboulsee A, et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology 2010;74:1877-1885.
  • Zhao Y, Petkau AJ, Traboulsee A, Riddehough A, Li DKB. Does MRI lesion activity regress in secondary progressive multiple sclerosis? Multiple Sclerosis 2010;16:434-442.
  • Bar-Or A, Rieckmann P, Traboulsee A, Yong VW. Targeting progressive neuroaxonal injury: lessons from multiple sclerosis. CNS Drugs 2011;25:783-799.
  • Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T, on behalf of the MAESTRO-01 Investigators. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology 2011;77:1551-1560.
  • Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, Konieczny A, Knappertz V, and the 16-Year Long-Term Follow-up Study Investigators. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS ONE 2011;6:e22444.
  • Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC, on behalf of the 16-Year Long-Term Follow-up Study Investigators. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 2011.
  • Laule C, Vavasour IM, Leung E, Li DKB, Kozlowski P, Traboulsee A, Oger J, MacKay AL, Moore GRW. Pathological basis of diffusely abnormal white matter: insights from magnetic resonance imaging and histology. Multiple Sclerosis 2011;17:144-150.
  • Liang AL, Vavasour IM, Madler B, Traboulsee A, Lang DJ. Short-term stability of T (1) and T(2) relaxation measures in multiple sclerosis normal appearing white matter. J Neurol 2011.
  • Martin N, Malfair D, Zhao Y, Li DKB, Traboulsee A, Lang D, Vertinsky AT. Comparison of MERGE and axial T2w-FSE sequences in the detection of multiple sclerosis lesions in the cervical spinal cord. American Journal of Roentgenology 2011 (accepted).
  • Patsopoulos NA and the Bayer Pharma MS Genetics Working Group, the Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist, ANZgene Consortium, GeneMSA, International Multiple Sclerosis Genetics Consortium and de Bakker PI. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 2011;70:897-912.
  • Riddell CA, Zhao Y, Li DKB, Petkau J, Riddehough A, Cutter GR, Traboulsee A. Evaluation of Safety Monitoring Guidelines based on MRI Lesion activity in Multiple Sclerosis. Neurology 2011;77:2089-2096.
  • Shoamanesh A, Chapman K, Traboulsee A. Postvaccination Miller Fisher Syndrome. Arch Neurol. 2011;68(10):1325-1327.
  • Shoamanesh A, Traboulsee A. Acute Disseminated Encephalomyelitis Following Influenza Vaccination. Vaccine 2011;29: 8182-8185.
  • Tam RC, Traboulsee A, Riddehough A, Sheikhzadeh F, Li DK. The impact of intensity variations in T1-hypointense lesions on clinical correlations in multiple sclerosis. Mult Scler 2011;17:949-957.
  • Uitdehaag B, Constantinescu C, Cornelisse P, Jeffrey D, Kappos L, Li DKB, Sandberg-Wollheim M, Traboulsee A, Verdun E, Rivera V. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord 2011;4:3-14.
  • Vavasour IM, Laule C, Li DK, Traboulsee AL, MacKay AL. Is the magnetization transfer ratio a marker for myelin in multiple sclerosis? J Magn Reson Imaging 2011;33:713-718.
  • Zhang Y, Traboulsee A, Zhao Y, Metz LM, Li DK. Texture analysis differentiates persistent and transient T1 black holes at acute onset in multiple sclerosis: a preliminary study. Multiple Sclerosis 2011;17:532-540.